J. Goldman & Co’s Insmed INSM Stock Holding History

J. Goldman & Co’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,000	Closed	-$2.29M	–	542
2025 Q1	$2.29M	Buy	+30,000	New	+$2.29M	0.06%	279
2024 Q3	–	Sell	-13,500	Closed	-$905K	–	532
2024 Q2	$905K	Buy	+13,500	New	+$524K	0.03%	314
2019 Q4	–	Sell	-30,000	Closed	-$529K	–	308
2019 Q3	$529K	Buy	+30,000	New	+$579K	0.04%	223
2019 Q1	–	Sell	-130,000	Closed	-$1.71M	–	292
2018 Q4	$1.71M	Buy	+130,000	New	+$2.07M	0.13%	151
2015 Q2	–	Sell	-27,000	Closed	-$562K	–	279
2015 Q1	$562K	Buy	+27,000	New	+$476K	0.03%	247

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

J. Goldman & Co's INSM Position: Q2 2026 in Review

J. Goldman & Co sold out of Insmed (INSM) in Q2 2026, closing a stake of 5,545 shares — an estimated $907K sold.

J. Goldman & Co first reported a position in INSM in Q4 2013 and held it in 25 quarters. The position peaked at $7.19M in Q4 2024. 667 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

J. Goldman & Co reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 5,545 Insmed shares in Q2 2026, an estimated $907K.
J. Goldman & Co first reported a position in Insmed in Q4 2013 and held it in 25 quarters.
J. Goldman & Co's Insmed position peaked at $7.19M in Q4 2024.
667 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.